1,027 material Form 8-K filings that 835 companies we cover made with the SEC in February 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Saul Centers reported fourth quarter 2024 results on February 28, 2025. Total revenue rose to $67.9 million from $66.7 million, but net income fell to $10.4 million from $17.5 million, and FFO per diluted share fell to $0.63 from $0.79. The company attributed the profit decline mainly to initial operations at Twinbrook Quarter Phase 1, which began carrying interest, taxes and other costs as expenses after its October 1, 2024 delivery, along with lower lease termination fees.
Q4 2024 total revenue was $67.9 million, up from $66.7 million in Q4 2023.
Net income available to common stockholders was $5.3 million, or $0.22 per basic and diluted share, versus $10.4 million, or $0.43, a year earlier.
Twinbrook Quarter Phase 1 reduced quarterly net income by $6.8 million compared with the prior-year quarter.
Lower lease termination fees of $2.4 million reduced results; commercial portfolio was 95.2% leased at December 31, 2024, up from 94.1%.
Middlesex Water reported 2024 net income of $44.4 million and diluted EPS of $2.47, up from $31.5 million and $1.76 in 2023. Revenue rose $25.6 million to $191.9 million, driven mainly by a New Jersey base rate increase and higher weather-driven customer demand, which points to stronger earnings for shareholders.
2024 net income of $44.4 million, up $12.8 million from 2023; diluted EPS of $2.47 versus $1.76
2024 revenues of $191.9 million, up $25.6 million from $166.3 million; Middlesex System revenues rose $19.9 million on the base rate increase approved in March 2024
Fourth quarter 2024 net income of $8.8 million and diluted EPS of $0.49, versus $5.8 million and $0.32 in the fourth quarter of 2023
Board declared a first quarter 2025 dividend of $0.34 per share, payable March 3, 2025; Ocean View water utility asset purchase for about $4.6 million expected to close by April 2025
Amneal reported fourth-quarter and full-year 2024 results on February 28, 2025. Net revenue rose 18% in the quarter and 17% for the year, while the GAAP net loss narrowed in the quarter but widened for the full year, and adjusted diluted EPS declined. The company also gave 2025 guidance for net revenue of $3.0 billion to $3.1 billion and adjusted EBITDA of $650 million to $675 million.
Q4 2024 net revenue was $731 million, up 18% from $617 million; GAAP net loss attributable to Amneal was $31 million, versus $99 million in Q4 2023.
Q4 2024 adjusted diluted EPS was $0.12, compared with $0.14 in Q4 2023.
Full-year 2024 net revenue was $2.79 billion, up 17%; GAAP net loss was $117 million, versus $84 million in 2023; adjusted diluted EPS was $0.58, down 9%.
2025 guidance: net revenue of $3.0 billion to $3.1 billion, adjusted EBITDA of $650 million to $675 million, and adjusted diluted EPS of $0.65 to $0.70.
AES reported full-year 2024 net income of $698 million, up from a net loss of $182 million in 2023, and Adjusted EPS of $2.14, above its $1.87 to $1.97 guidance range. Adjusted EBITDA fell $189 million to $2,639 million and total revenue declined to $12,278 million from $12,668 million, while the company initiated 2025 guidance for Adjusted EBITDA of $2,650 million to $2,850 million and Adjusted EPS of $2.10 to $2.26.
Full-year 2024 diluted EPS from continuing operations was $2.37, compared with $0.34 in 2023
Adjusted EBITDA was $2,639 million, within the $2,600 million to $2,900 million guidance range but down from $2,828 million in 2023
2025 guidance: Adjusted EBITDA of $2,650 million to $2,850 million and Adjusted EPS of $2.10 to $2.26
Quarterly dividend of $0.17595 expected to be maintained
MasTec reported fourth quarter and full-year 2024 results on February 27, 2025, with revenue and GAAP net income both higher than in 2023. The company also issued initial 2025 guidance, including $13.45 billion in revenue and GAAP net income of $327 million to $366 million, and expects a GAAP net loss of $1 million in the first quarter of 2025.
Q4 2024 revenue was $3.4 billion, up from $3.3 billion; GAAP net income was $84.7 million, versus $1.2 million in Q4 2023.
Full-year 2024 GAAP net income was $199.4 million, or $2.06 per diluted share, compared with a net loss of $47.3 million in 2023.
2025 guidance: revenue of $13.45 billion, GAAP diluted EPS of $3.75 to $4.24, and adjusted EBITDA of $1.10 billion to $1.15 billion.
Estimated 18-month backlog reached a record $14.3 billion at December 31, 2024; net debt leverage ratio was 1.8x.
NW Natural Holdings reported that 2024 net income fell 16% to $78.9 million, or $2.03 per share, from $93.9 million, or $2.59 per share, in 2023, and annual operating revenue fell 4% to $1.15 billion. Excluding a non-cash regulatory disallowance and SiEnergy transaction costs, adjusted EPS was $2.33. The company also initiated 2025 GAAP EPS guidance of $2.66 to $2.86, which shareholders will weigh against the lower 2024 results.
2024 net income $78.9 million ($2.03 per share) vs. $93.9 million ($2.59 per share) in 2023; adjusted EPS $2.33
Fourth-quarter operating revenue rose 4% to $370.9 million, while fourth-quarter diluted EPS was $1.12 vs. $1.21
2025 GAAP EPS guidance $2.66 to $2.86; adjusted EPS guidance $2.75 to $2.95; long-term EPS growth target of 4% to 6% reaffirmed
Quarterly dividend of $0.49 per share paid Feb. 14, 2025; indicated annual rate $1.96 per share
Ellington Financial reported net income attributable to common stockholders of $22.4 million, or $0.25 per share, for the quarter ended December 31, 2024, up from $16.2 million, or $0.19 per share, in the third quarter. Adjusted distributable earnings were $40.6 million, or $0.45 per share, which covered the $0.39 per share in dividends for the quarter. Book value per common share was $13.52 as of December 31, 2024.
Net income attributable to common stockholders of $22.4 million, or $0.25 per share, versus $16.2 million, or $0.19 per share, in the third quarter of 2024
Adjusted distributable earnings of $40.6 million, or $0.45 per share, versus $0.39 per share in dividends for the quarter
Book value per common share of $13.52 as of December 31, 2024
Monthly dividend of $0.13 per common share declared on February 10, 2025
National HealthCare reported full-year 2024 net operating revenues and grant income of $1,307,382,000, up 14.5% from 2023, and GAAP net income attributable to NHC of $101,927,000, up from $66,798,000. Fourth-quarter GAAP net income fell to $6,081,000 from $28,406,000, mainly due to an unrealized loss of $25,332,000 on marketable equity securities, while adjusted net income rose 62.7% to $25,954,000.
Full-year 2024 GAAP diluted EPS was $6.53, compared with $4.34 in 2023; adjusted diluted EPS was $4.93, compared with $3.55.
Fourth-quarter 2024 GAAP diluted EPS was $0.39, compared with $1.83 in the fourth quarter of 2023; adjusted diluted EPS was $1.66, compared with $1.03.
Full-year revenue growth reflected a 9.4% increase in same-facility net operating revenues and the August 1, 2024 acquisition of White Oak Manor.
The filing does not include forward-looking guidance for 2025; the full press release is attached as Exhibit 99.1.
LeMaitre Vascular reported preliminary fourth-quarter 2024 results, with net sales of $55.7 million, up 14% from a year earlier, and diluted EPS of $0.49 versus $0.38. The company also gave 2025 guidance of $235.4 million to $242.8 million in sales and $2.15 to $2.32 in EPS, and raised its quarterly dividend 25% to $0.20 per share. Sales and earnings growth, plus the dividend increase and a share repurchase authorization of up to $75.0 million, are the main items for shareholders.
Q4 2024 net income was $11.2 million, versus $8.5 million in Q4 2023; operating income was $12.9 million, up 26%.
Gross margin was 69.3%, up from 68.1% in Q4 2023.
2025 full-year sales guidance is $235.4 million to $242.8 million, compared with 2024 sales of $219.9 million.
The quarterly dividend rises to $0.20 per share, payable March 27, 2025; the board authorized up to $75.0 million in buybacks through February 17, 2026.
Tidewater reported fourth-quarter 2024 revenue of $345.1 million, up from $302.7 million a year earlier, while quarterly net income of $36.9 million ($0.70 per diluted share) was roughly flat against $37.7 million ($0.70) in the prior-year quarter. The company also initiated 2025 revenue guidance of $1.32 billion to $1.38 billion and approved a new share repurchase program of up to $90.3 million, which management said is the maximum permitted under its existing debt agreements.
Q4 2024 revenue of $345.1 million, compared with $302.7 million for Q4 2023
Q4 2024 net income of $36.9 million ($0.70 per diluted share), compared with $37.7 million ($0.70) for Q4 2023
Full-year 2024 net income of $180.7 million ($3.40 per diluted share), up 85.9% from 2023
2025 guidance: revenue of $1.32 billion to $1.38 billion and gross margin of 48% to 50%; new buyback authorization of $90.3 million
Astrana Health reported fourth-quarter and full-year 2024 results. Revenue grew sharply, but net income attributable to Astrana fell from $60.7 million to $43.1 million for the year, and the fourth quarter swung to a $7.0 million net loss. The company also gave 2025 guidance of $2.5 billion to $2.7 billion in total revenue and $170 million to $190 million in Adjusted EBITDA.
Full-year 2024 total revenue was $2,034.5 million, up 47% from $1,386.7 million; diluted EPS was $0.90, versus $1.29 in 2023.
Fourth-quarter 2024 net loss attributable to Astrana was $7.0 million, compared with income of $12.4 million a year earlier, on revenue of $665.2 million, up 88%.
2025 guidance: total revenue of $2,500 million to $2,700 million and Adjusted EBITDA of $170 million to $190 million, excluding acquisitions not yet closed.
On February 26, 2025, the company amended its credit agreement with Truist Bank, providing for $1.3 billion in total facilities including a $745.0 million delayed draw term loan.
Amphastar Pharmaceuticals reported fourth-quarter and full-year 2024 results on February 27, 2025. Net revenues rose 5% in the quarter and 14% for the year, and GAAP diluted EPS increased from the prior-year periods, though fourth-quarter gross margin fell to 46.5% from 54.0%.
Q4 net revenues were $186.5 million, up from $178.1 million; GAAP diluted EPS was $0.74 versus $0.68 and adjusted non-GAAP diluted EPS was $0.92 versus $0.88.
Full-year net revenues were $732.0 million, up from $644.4 million; GAAP diluted EPS was $3.06 versus $2.60.
Q4 gross margin was 46.5% versus 54.0%, mainly due to lower other revenues after the Lilly Transition Service Agreement with Lilly expired in Q4 2024; BAQSIMI product revenues were $41.8 million in the quarter.
HCI Group reported fourth-quarter 2024 net income after noncontrolling interests of $2.6 million, down from $38.1 million a year earlier, as losses from Hurricane Milton and higher ceded reinsurance premiums cut profit. For the full year, pre-tax income rose to $173.4 million and diluted EPS rose to $8.89 from $7.62, and the company said it plans to keep rates flat for the foreseeable future.
Q4 2024 GAAP diluted EPS was $0.23, versus $3.40 in Q4 2023; non-GAAP adjusted diluted EPS was $0.31, versus $3.22.
Q4 2024 losses and loss adjustment expenses were $110.7 million, including a net loss of $78.0 million from Hurricane Milton.
Full-year 2024 total revenue was $750.1 million, up from $550.7 million in 2023, and consolidated gross premiums earned rose 41.5% to $1,083.2 million.
The company will hold its earnings call on February 27, 2025 at 4:45 p.m. Eastern time.
Arcosa reported fourth quarter 2024 revenue up 14% to $666.2 million, helped by the $1.2 billion Stavola acquisition completed October 1, 2024, but posted a net loss of $7.7 million versus net income of $27.1 million a year earlier. Acquisition-related expenses of $15.6 million and higher interest expense weighed on results, while Adjusted EBITDA rose 52% to $128.3 million. The company guided to 2025 revenues of $2.8 billion to $3.0 billion and Adjusted EBITDA of $545 million to $595 million, with GAAP profit trends and guidance pointing in different directions for shareholders.
Q4 2024 revenue was $666.2 million, up 14% from $582.2 million; net loss was $7.7 million, or $0.16 per diluted share, versus net income of $27.1 million, or $0.56 per share, in Q4 2023.
Q4 Adjusted EBITDA rose 52% to $128.3 million; Adjusted Diluted EPS fell 32% to $0.46 from $0.68.
Full year 2025 guidance: consolidated revenues of $2.8 billion to $3.0 billion and Adjusted EBITDA of $545 million to $595 million.
Q4 free cash flow was $199.2 million; year-end net debt to Adjusted EBITDA was 2.9x, down from 3.4x at the end of the third quarter.
Erie Indemnity reported fourth-quarter 2024 net income of $152.0 million, or $2.91 per diluted share, up from $110.9 million, or $2.12, a year earlier. Full-year 2024 net income rose to $600.3 million, or $11.48 per diluted share, from $446.1 million, or $8.53, in 2023. The board also declared a quarterly Class A dividend of $1.365 per share, payable April 22, 2025.
Q4 2024 net income $152.0 million, or $2.91 per diluted share, versus $110.9 million, or $2.12, in Q4 2023
Full-year 2024 net income $600.3 million, or $11.48 per diluted share, versus $446.1 million, or $8.53, in 2023
Quarterly Class A dividend of $1.365 per share (Dividend No. 379), record and ex-dividend date April 7, 2025, payable April 22, 2025
Pre-recorded webcast on the results scheduled for 10:00 a.m. ET on February 28, 2025
Assured Guaranty reported fourth quarter 2024 net income attributable to the company of $18 million, or $0.35 per diluted share, down from $376 million, or $6.40 per share, a year earlier. The prior-year quarter included a $208 million benefit from tax law changes, and full-year 2024 net income fell to $376 million, or $6.87 per share, from $739 million, or $12.30 per share. For shareholders, the decline in reported earnings is large, though the company also repurchased $502 million of shares in 2024.
Q4 2024 adjusted operating income was $66 million, or $1.27 per share, versus $338 million, or $5.75 per share, in Q4 2023.
Full-year 2024 adjusted operating income was $389 million, or $7.10 per share, versus $648 million, or $10.78 per share, in 2023.
Q4 2024 total revenues were $156 million, versus $327 million in Q4 2023; full-year revenues were $872 million, versus $1,373 million.
As of February 27, 2025, the company was authorized to buy back about $276 million of its common shares, and it expects a gain of about $103 million in Q1 2025 from the LBIE litigation.
Monster Beverage reported fourth-quarter and full-year 2024 results, with net sales up 4.7% in the quarter to $1.81 billion. Reported net income fell 26.2% to $270.7 million because of a $130.7 million Alcohol Brands impairment charge, while adjusted net income fell 6.6% to $375.7 million. Shareholders are weighing solid sales growth against lower reported earnings and a large non-cash charge.
Q4 2024 net sales rose 4.7% to $1.81 billion; on a foreign-currency-adjusted basis, sales rose 7.8%.
Reported Q4 diluted EPS was $0.28, down from $0.35; adjusted diluted EPS was $0.38, unchanged from the prior year.
Full-year 2024 net sales rose 4.9% to $7.49 billion, and reported net income fell 7.5% to $1.51 billion.
No shares were repurchased in Q4 2024; about $500.0 million remained available under the repurchase program as of February 26, 2025.
Tutor Perini reported fourth-quarter and full-year 2024 results, with 2024 revenue up 12% to $4.3 billion and a net loss attributable to the company of $163.7 million, or $3.13 per diluted share, versus a $171.2 million loss in 2023. The company also reported record operating cash flow of $503.5 million and a record backlog of $18.7 billion, and guided to 2025 EPS of $1.50 to $1.90.
2024 revenue was $4.3 billion, up 12% from 2023, and the net loss attributable to the company narrowed from $171.2 million to $163.7 million.
Net cash provided by operating activities was $503.5 million in 2024, up 63%, and total debt was reduced by $477 million, or 52%, since the end of 2023.
Backlog reached $18.7 billion as of December 31, 2024, up 84% from $10.2 billion a year earlier.
For 2025, the company expects double-digit revenue growth and EPS of $1.50 to $1.90.
HP reported fiscal first-quarter revenue of $13.5 billion, up 2.4% from a year earlier, while GAAP diluted EPS fell to $0.59 from $0.62. HP also approved an expansion of its restructuring plan, adding about $0.3 billion in annualized savings and about $150 million in charges, with 1,000 to 2,000 additional gross workforce reductions, and it held its fiscal 2025 outlook.
Q1 fiscal 2025 net revenue $13.5 billion, up 2.4%; GAAP diluted EPS $0.59 versus $0.62, within the $0.57 to $0.63 outlook
Non-GAAP diluted EPS $0.74 versus $0.81 a year earlier, within the $0.70 to $0.76 outlook
Restructuring amendment adds about $0.3 billion in fiscal 2025 savings, bringing the total to about $1.9 billion, with about $150 million in additional charges
Incremental gross workforce reductions of about 1,000 to 2,000 employees, varying by country; fiscal 2025 non-GAAP EPS outlook of $3.45 to $3.75 held
American Healthcare REIT reported fourth-quarter and full-year 2024 results on February 27, 2025, and issued full-year 2025 guidance. The fourth-quarter GAAP net loss per diluted share narrowed to $(0.21) from $(0.42) a year earlier, and normalized FFO per diluted share rose to $0.40 from $0.38, while full-year normalized FFO was $1.41 versus $1.40 in 2023. For 2025, the company expects normalized FFO of $1.56 to $1.60 per diluted share and total portfolio same-store NOI growth of 7.0% to 10.0%.
Q4 2024 GAAP net loss attributable to controlling interest was $(31.8) million, or $(0.21) per diluted share, versus $(27.4) million, or $(0.42), in Q4 2023.
Full-year 2024 normalized FFO was $1.41 per diluted share; total portfolio same-store NOI grew 17.7%.
2025 guidance: normalized FFO of $1.56 to $1.60 per diluted share and net income of $0.26 to $0.30 per diluted share, versus a 2024 net loss of $(0.29).
Company raised about $1.36 billion of gross equity in 2024, including $120.2 million through its at-the-market program in Q4.
Rocket Lab reported fourth-quarter 2024 revenue of $132.4 million, up from $60.0 million a year earlier, and full-year 2024 revenue of $436.2 million, up 78% from $244.6 million. The net loss widened slightly, to $52.3 million in the quarter and $190.2 million for the year, and the company guided first-quarter 2025 revenue to $117 million to $123 million.
Q4 2024 revenue was $132.4 million versus $60.0 million in Q4 2023; Q4 net loss was $52.3 million versus $50.5 million.
Full-year 2024 revenue was $436.2 million versus $244.6 million in 2023; full-year net loss was $190.2 million versus $182.6 million.
Q1 2025 guidance calls for revenue of $117 million to $123 million, with GAAP gross margins of 25% to 27%.
Electron launched 16 times in 2024, and the company reported more than $450 million in newly secured contracts.
TransMedics reported fourth-quarter and full-year 2024 results on February 27, 2025, with revenue of $121.6 million for the quarter, up 50%, and $441.5 million for the year, up 83%. The company posted full-year net income of $35.5 million, or $1.01 per diluted share, compared with a net loss of $25.0 million in 2023, and expects 2025 revenue of $530 million to $552 million.
Q4 2024 revenue of $121.6 million, up 50% from $81.2 million; Q4 net income of $6.9 million, or $0.19 per diluted share
Full-year 2024 gross margin of 59.4%, down from 63.8% in 2023; operating expenses of $224.6 million
2025 revenue outlook of $530 million to $552 million, representing 20% to 25% growth
Metallus reported a fourth-quarter 2024 net loss of $21.4 million, or $0.50 per diluted share, compared with net income of $1.3 million, or $0.03 per share, a year earlier. Full-year 2024 net income fell to $1.3 million from $69.4 million, and the company expects first-quarter 2025 adjusted EBITDA to be higher than the fourth quarter of 2024.
Q4 2024 net sales were $240.5 million, down 27% from $328.1 million in Q4 2023 but up 6% from $227.2 million in Q3 2024.
Q4 2024 adjusted EBITDA was $8.3 million, compared with $35.7 million in Q4 2023.
Full-year 2024 net sales were $1.1 billion, down 20% from 2023, and operating cash flow was $40.3 million.
The company repurchased $37.6 million of common shares in 2024 and has $102.8 million remaining on its share repurchase program.
Solventum reported fourth-quarter 2024 sales up 1.9% to $2.074 billion, but GAAP diluted EPS fell to $0.17 from $1.57 a year earlier, and adjusted EPS fell to $1.41 from $2.17. The company also introduced 2025 guidance for organic sales growth, adjusted EPS and free cash flow, but said the guidance still includes the Purification and Filtration segment it agreed to sell and will be updated after that deal closes.
Q4 2024 sales were $2.074 billion, up 1.9%; organic sales rose 2.3%
GAAP operating income was $136 million versus $406 million a year earlier; adjusted operating margin was 20.4% versus 25.9%
2025 guidance: organic sales growth of 1.0% to 2.0%, adjusted EPS of $5.45 to $5.65, free cash flow of $450 million to $550 million
Guidance includes Purification and Filtration, which Solventum announced it would sell on February 25, 2025
DoubleVerify reported fourth-quarter 2024 revenue of $190.6 million, up 11% from a year earlier, but net income fell to $23.4 million from $33.1 million. The company also agreed to acquire Rockerbox for $85 million in cash and guided first-quarter 2025 revenue to $151 million to $155 million, with full-year 2025 revenue growth of about 10%. Shareholders see revenue growth alongside lower profit, plus a new acquisition that adds to the company's spending.
Q4 2024 revenue of $190.6 million, up 11%; Q4 net income of $23.4 million versus $33.1 million in Q4 2023
Full-year 2024 revenue of $656.8 million, up 15%; full-year net income of $56.2 million versus $71.5 million in 2023
Q1 2025 revenue guidance of $151 million to $155 million; full-year 2025 revenue growth of approximately 10%
Agreed to acquire Rockerbox, Inc. for $85 million in cash, subject to customary adjustments, announced February 26, 2025
Acadia Healthcare reported fourth-quarter 2024 revenue of $774.2 million, up 4.2% from a year earlier, but net income attributable to Acadia fell to $32.6 million, or $0.35 per diluted share, from $57.7 million, or $0.63, in the prior-year quarter. The company also issued 2025 guidance, including revenue of $3.3 to $3.4 billion and adjusted EPS of $2.50 to $2.80, and authorized a $300 million share repurchase program.
Q4 2024 revenue $774.2 million, up 4.2%; adjusted EBITDA $153.1 million versus $171.6 million a year earlier
Full-year 2024 revenue $3.15 billion, up 7.7%; net income attributable to Acadia $255.6 million versus a loss of $21.7 million in 2023
2025 guidance: revenue $3.3 to $3.4 billion, adjusted EBITDA $675 to $725 million, adjusted EPS $2.50 to $2.80
Board authorized share repurchases of up to $300 million with no expiration date; conference call scheduled February 28, 2025
PTC Therapeutics reported fourth-quarter and full-year 2024 results. Revenue fell from a year earlier, while the net loss narrowed, with a $99.9 million gain on sale of a priority review voucher offsetting part of a $159.5 million intangible asset impairment. The company guided full-year 2025 total revenue to between $600 million and $800 million.
Q4 2024 total revenue was $213.2 million, versus $307.1 million in Q4 2023; full-year 2024 revenue was $806.8 million, versus $937.8 million in 2023.
Q4 2024 net loss was $65.9 million, or $0.85 per share, versus $155.8 million, or $2.06 per share, in Q4 2023.
Q4 2024 results include a $159.5 million intangible asset impairment and a $99.9 million gain on sale of a priority review voucher.
2025 guidance: total revenue of $600 million to $800 million; cash, cash equivalents and marketable securities were $1,139.7 million on December 31, 2024.
ICU Medical reported fourth quarter 2024 revenue of $629.8 million, up from $587.9 million a year earlier, and adjusted diluted EPS of $2.11 versus $1.57. GAAP net loss widened to $23.8 million, or $(0.97) per share, from $17.1 million, or $(0.71) per share, a year earlier. The company also gave fiscal 2025 guidance for GAAP net loss of $(45) million to $(28) million and adjusted EPS of $6.55 to $7.25, excluding a pending IV Solutions joint venture.
Q4 2024 revenue was $629.8 million, versus $587.9 million in Q4 2023; GAAP gross margin was 36.1%, versus 29.2%.
Q4 2024 adjusted EBITDA was $105.5 million, versus $86.3 million; GAAP net loss was $(23.8) million, or $(0.97) per diluted share.
FY2025 guidance: GAAP net loss of $(45) million to $(28) million; adjusted EBITDA of $395 million to $425 million, excluding the IV Solutions joint venture.
The IV Solutions joint venture is expected to close in Q2 2025 and, if so, reduce 2025 adjusted EBITDA guidance by $15 million to $20 million.
Sunrun reported fourth-quarter and full-year 2024 results. Revenue was flat in Q4 and down 10% for the year, and a $3.1 billion non-cash goodwill impairment drove a large GAAP net loss. The company reported Cash Generation of $34.2 million in Q4 and gave 2025 Cash Generation guidance of $200 million to $500 million.
Q4 2024 total revenue was $518.5 million, up $1.9 million, or 0%, from Q4 2023; full-year 2024 revenue was $2.0 billion, down 10%.
Q4 2024 net loss attributable to common stockholders was $2.8 billion, or $12.51 per share, including the $3.1 billion goodwill impairment; non-GAAP net income was $360.9 million, or $1.41 per diluted share.
2025 Cash Generation guidance is $200 million to $500 million for the full year and $40 million to $50 million for Q1 2025.
Progyny reported fourth-quarter and full-year 2024 results on February 27, 2025. Revenue grew in both periods, but net income declined, mainly because of a higher income tax provision tied to equity compensation. For 2025, the company guided revenue to $1.175 billion to $1.225 billion and net income to $45.0 million to $53.9 million, a range below 2024's $54.3 million, and said a large client did not renew its services agreement for 2025.
Q4 2024 revenue was $298.4 million, up 10.6%; net income was $10.5 million, or $0.12 per diluted share, versus $13.5 million, or $0.13, a year earlier.
Full-year 2024 revenue was $1.167 billion, up 7.2%; net income was $54.3 million, or $0.57 per diluted share, versus $62.0 million, or $0.62.
2025 guidance: revenue of $1.175 billion to $1.225 billion and net income of $45.0 million to $53.9 million.
Q1 2025 guidance: revenue of $300.0 million to $318.0 million and net income of $15.0 million to $17.8 million.
Fox Factory reported fourth-quarter fiscal 2024 net sales of $352.8 million, up 6.1% from a year earlier, but GAAP earnings per diluted share were breakeven versus $0.10 a year earlier, and adjusted earnings per diluted share fell to $0.31 from $0.48. The company also issued fiscal 2025 guidance calling for net sales of $1.385 billion to $1.485 billion and adjusted earnings per diluted share of $1.60 to $2.60, excluding any effects of ongoing tariff developments.
Q4 net sales were $352.8 million, up from $332.5 million; Specialty Sports Group sales rose 33.3%, while Aftermarket Applications Group and Powered Vehicles Group sales fell 7.1% and 1.8%.
Q4 GAAP net loss attributable to FOX stockholders was $0.1 million, compared with net income of $4.1 million a year earlier; adjusted EPS was $0.31 versus $0.48.
Fiscal 2024 net sales fell 4.8% to $1,393.9 million, and GAAP EPS was $0.16 versus $2.85; total debt was $705.1 million at January 3, 2025.
Fiscal 2025 guidance: net sales of $1.385 billion to $1.485 billion and adjusted EPS of $1.60 to $2.60; first-quarter adjusted EPS guidance is $0.12 to $0.32.
Arlo Technologies reported fourth-quarter revenue of $121.6 million, down from $135.1 million a year earlier, and a GAAP net loss of $4.9 million, compared with net income of $0.7 million in the prior-year quarter. For full-year 2024, revenue rose to $510.9 million from $491.2 million, but the GAAP net loss widened to $30.5 million, and the company guided first-quarter 2025 revenue to $114 million to $124 million.
Q4 2024 revenue $121.6 million vs $135.1 million in Q4 2023; GAAP net loss per share $(0.05) vs $0.01 income
Full-year 2024 revenue $510.9 million vs $491.2 million; GAAP net loss $30.5 million vs $22.0 million
Annual recurring revenue ended at $257.3 million, up 22.5% year over year
Q1 2025 outlook: revenue $114 million to $124 million; GAAP EPS $(0.06) to $0.00
DiamondRock Hospitality reported a fourth-quarter 2024 net loss attributable to common stockholders of $13.7 million, or $0.07 per diluted share, compared with net income of $8.5 million a year earlier, after a $32.6 million impairment loss on the Westin Washington D.C. City Center. Total revenues rose 5.9% to $279.1 million and Adjusted EBITDA rose 19.9% to $68.7 million, and the company issued 2025 guidance calling for Adjusted FFO per share of $0.94 to $1.06.
Q4 2024 net loss of $13.7 million, or $0.07 per diluted share, versus net income of $8.5 million in Q4 2023
Q4 2024 total revenues of $279.1 million, up 5.9%; Adjusted EBITDA of $68.7 million, up 19.9%
Full year 2024 net income attributable to common stockholders of $38.2 million, or $0.18 per diluted share, versus $76.5 million in 2023; Adjusted FFO per share of $1.01, up 8.6%
2025 guidance: Adjusted EBITDA of $275 million to $300 million and Adjusted FFO per share of $0.94 to $1.06; Westin Washington D.C. sold for $92.0 million on February 19, 2025
Edison International reported fourth-quarter 2024 net income of $340 million, or $0.88 per share, down from $378 million, or $0.99 per share, a year earlier. Full-year 2024 GAAP EPS rose to $3.33 from $3.12, and core EPS rose to $4.93 from $4.76. The company revised its 2025 core EPS guidance to $5.94-$6.34, which includes the impact of the TKM settlement, and the filing does not state the prior range.
Q4 2024 core EPS was $1.05, compared with $1.28 a year earlier; core earnings were $405 million versus $490 million.
Full-year 2024 operating revenue was $17.6 billion, up from $16.3 billion in 2023.
TKM settlement approved, authorizing $1.6 billion of cost recovery for pre-AB 1054 wildfire costs.
Quarterly dividend of $0.8275 per share declared, payable April 30, 2025, to holders of record on April 7, 2025.
Duolingo reported fourth-quarter and full-year 2024 results, with Q4 revenue of $209.6 million, up 39% year over year, and full-year revenue of $748.0 million, up 41%. Net income rose to $88.6 million for 2024 from $16.1 million in 2023, and the company issued initial guidance for 2025 revenue of $962.5 million to $978.5 million.
Q4 2024 revenue was $209.6 million, up 39% year over year; Q4 net income was $13.9 million, compared with $12.1 million a year earlier.
FY 2024 revenue was $748.0 million, up 41%; FY 2024 net income was $88.6 million, compared with $16.1 million in 2023.
Q4 2024 daily active users reached 40.5 million, up 51% year over year, and paid subscribers totaled 9.5 million, up 43%.
2025 guidance: bookings of $1,082 million to $1,098 million, revenue of $962.5 million to $978.5 million, and Adjusted EBITDA of $259.9 million to $274.0 million.
Bloom Energy reported fourth-quarter 2024 revenue of $572.4 million, up 60.4% from a year earlier, and record full-year 2024 revenue of $1.47 billion, up 10.5%. The company returned to a fourth-quarter GAAP net profit of $104.8 million, and its full-year 2024 GAAP net loss narrowed to $29.2 million from $302.1 million in 2023, while it issued full-year 2025 revenue guidance of $1.65 billion to $1.85 billion.
Q4 2024 revenue of $572.4 million, up 60.4% from $356.9 million in Q4 2023; Q4 GAAP net profit of $104.8 million
Full-year 2024 revenue of $1,473.9 million, up 10.5%; full-year GAAP net loss of $29.2 million, or $0.13 per share, versus a $302.1 million loss in 2023
2025 outlook: revenue of $1.65 billion to $1.85 billion, non-GAAP gross margin of about 29%, and non-GAAP operating income of $135 million to $165 million
NetApp reported third-quarter fiscal 2025 net revenues of $1.64 billion, up 2% year over year, while GAAP net income fell to $299 million and GAAP diluted EPS to $1.44 from $1.48. The company also gave fourth-quarter and updated full-year fiscal 2025 revenue and EPS ranges, and announced a new CFO effective March 10, 2025.
Q3 net revenues $1.64 billion vs. $1.61 billion a year earlier; non-GAAP EPS $1.91 vs. $1.94
Q3 GAAP net income $299 million vs. $313 million; cash provided by operations $385 million vs. $484 million
Cytokinetics reported fourth-quarter and full-year 2024 results on February 27, 2025. Revenue rose sharply, but the net loss grew in dollar terms, and the company guided to 2025 GAAP operating expense of $670 million to $710 million as it prepares for a possible aficamten launch.
Q4 2024 total revenues were $16.9 million, up from $1.7 million in Q4 2023, benefiting from a $15.0 million upfront payment from Corxel.
Q4 2024 net loss was $150.0 million, or $(1.26) per share, versus $136.9 million, or $(1.38) per share, in Q4 2023.
Full-year 2024 net loss was $589.5 million, or $(5.26) per share, versus $526.2 million, or $(5.45) per share, in 2023.
2025 GAAP operating expense guidance is $670 million to $710 million; cash, cash equivalents and investments were approximately $1.2 billion at December 31, 2024.
Mosaic reported fourth quarter and full year 2024 results. Full-year net sales fell 19% to $11.1 billion and net income fell 85% to $175 million, with a $642 million foreign exchange loss weighing on results. Management expects phosphate and potash volumes to recover in 2025 and gave production, sales volume, price and capital expenditure assumptions for the year.
Q4 2024 net income was $169 million, down from $365 million in Q4 2023; Q4 adjusted EBITDA was $594 million versus $646 million
Full-year 2024 adjusted EBITDA was $2.2 billion, down 20% from 2023; full-year diluted EPS was $0.55
Notable items reduced 2024 EPS by $1.43, mainly a $642 million foreign currency transaction loss, partly offset by a $522 million Ma'aden gain
2025 guidance includes potash production of 8.7-9.1 million tonnes and phosphate production of 7.2-7.6 million tonnes, with capital expenditures of $1.2-1.3 billion
Collegium reported record fourth-quarter and full-year 2024 product revenues and reaffirmed its 2025 guidance. Q4 GAAP net income fell to $12.5 million from $31.9 million a year earlier, though full-year GAAP net income rose to $69.2 million from $48.2 million. Shirley Kuhlmann, executive vice president, chief administrative officer, general counsel and secretary, will leave the company effective March 7, 2025.
Q4 product revenues, net were $181.9 million, up 22% from $149.7 million; Q4 GAAP diluted EPS was $0.36 versus $0.82 a year earlier
Full-year 2024 product revenues, net were $631.4 million, up 11%; full-year GAAP net income was $69.2 million versus $48.2 million
2025 guidance reaffirmed: product revenues, net of $735.0 to $750.0 million and adjusted EBITDA of $435.0 to $450.0 million
Shirley Kuhlmann steps down effective March 7, 2025; her departure is treated as a termination without cause under her existing employment agreement
Alignment Healthcare reported fourth-quarter and full-year 2024 results on February 27, 2025, with revenue growth of 50.7% in the quarter and 48.3% for the year. Net losses narrowed from the prior year, and the company issued 2025 guidance of $3.72 billion to $3.78 billion in revenue and $35 million to $60 million in adjusted EBITDA.
Q4 2024 total revenue was $701.2 million, up 50.7% year over year; net loss was $(31.1) million versus $(47.2) million a year earlier.
Full-year 2024 total revenue was $2,703.6 million, up 48.3%; net loss was $(128.1) million versus $(148.2) million in 2023.
2025 guidance: revenue of $3.72 billion to $3.78 billion and adjusted EBITDA of $35 million to $60 million.
Health plan membership was about 189,100 at December 31, 2024, up 58.6% year over year.
International Bancshares Corporation reported 2024 net income of $409.2 million, or $6.57 per diluted share, down from $411.8 million, or $6.62 per diluted share, in 2023. For the fourth quarter, net income rose to $115.1 million, or $1.85 per diluted share, from $106.4 million, or $1.71 per diluted share, a year earlier. Shareholders see a slight annual decline offset by stronger fourth-quarter results.
Full-year 2024 net income was $409.2 million, down about 0.6% from $411.8 million in 2023.
Full-year 2024 diluted EPS was $6.57, down about 0.8% from $6.62.
Fourth-quarter 2024 net income was $115.1 million, up about 8.2% from $106.4 million; diluted EPS was $1.85, up 8.1% from $1.71.
Total assets were about $15.7 billion at December 31, 2024, versus $15.1 billion a year earlier.
Essential Utilities reported fourth-quarter 2024 net income of $184.8 million, or $0.67 per share, up from $0.50 a year earlier, and full-year 2024 net income of $595.3 million, or $2.17 per share, up 17%. Full-year results include a gain on the sale of the Pittsburgh-area energy projects, and adjusted full-year EPS was $1.97 (non-GAAP). The company affirmed its 2025 EPS guidance of $2.07 to $2.11 and its multi-year EPS growth target of 5 to 7% a year through 2027.
Q4 2024 revenue was $604.4 million, up 26.1% from $479.4 million; Q4 net income was $184.8 million.
Full-year 2024 revenue was $2,086.1 million, up 1.6%, and net income was $595.3 million, or $2.17 per share.
Adjusted full-year 2024 EPS was $1.97 (non-GAAP), excluding one-time gains and weather-related items.
The board declared a quarterly dividend of $0.3255 per share, payable June 2, 2025, to holders of record on May 13, 2025.
California Water Service Group reported fourth quarter and full-year 2024 results on February 27, 2025. Full-year operating revenue rose to $1.037 billion from $794.6 million and diluted EPS rose to $3.25 from $0.91, but fourth-quarter net income fell to $19.7 million ($0.33 per diluted share) from $30.1 million ($0.52) despite higher quarterly revenue. For shareholders, the filing also shows the CPUC postponed the company's next cost of capital application to May 1, 2026, and the company declared a $0.30 quarterly dividend plus a $0.04 special dividend.
Full-year 2024 net income attributable to the company was $190.8 million, or $3.25 diluted EPS, versus $51.9 million, or $0.91, in 2023
Q4 2024 operating revenue was $222.2 million, up from $214.5 million, while Q4 net income was $19.7 million versus $30.1 million a year earlier
Capital investment reached a record $471.0 million in 2024, up 23% from the prior year
The CPUC postponed the cost of capital application to May 1, 2026 and the company declared a $0.30 quarterly dividend plus a $0.04 special dividend
Standard Motor Products reported fourth-quarter 2024 net sales of $343.4 million, up 18.1%, helped by the Nissens acquisition, which closed November 1. The company swung to a GAAP loss from continuing operations of $0.8 million, or $0.04 per diluted share, versus earnings of $7.2 million a year earlier, while adjusted EPS rose to $0.47 from $0.37. The company expects 2025 sales growth in the mid-teens and adjusted EBITDA margin of 10.0-11.0%, but its results include acquisition-related charges and debt rose to $517.9 million of net debt.
Q4 2024 net sales $343.4 million, up 18.1%; up 5.8% excluding Nissens, which contributed $35.7 million
Q4 GAAP loss from continuing operations $0.8 million ($0.04 per diluted share) vs. earnings of $7.2 million ($0.32) in Q4 2023
Full-year 2024 net sales $1.46 billion, up 7.8%; adjusted diluted EPS $3.17, up 8.6%
2025 outlook: sales growth in the mid-teens and adjusted EBITDA of 10.0-11.0%; quarterly dividend of 31 cents payable March 3, 2025
ACI Worldwide reported full-year 2024 revenue of $1.594 billion, up 10%, and net income of $203 million, up 67%. Fourth-quarter revenue fell to $453 million from $477 million, and fourth-quarter net income declined to $98.6 million from $122.6 million. The company guided 2025 revenue to $1.685 billion to $1.715 billion, or 7% to 9% growth on a constant currency basis, and adjusted EBITDA to $480 million to $495 million.
Full-year 2024 total revenue of $1.594 billion, up 10%; net income of $203 million, up 67%; adjusted EBITDA of $466 million, up 18%.
Q4 2024 revenue of $453 million versus $477 million a year earlier; Q4 net income of $98.6 million versus $122.6 million; diluted EPS of $0.93 versus $1.12.
2025 guidance: revenue of $1.685 billion to $1.715 billion and adjusted EBITDA of $480 million to $495 million; Q1 2025 revenue expected at $360 million to $370 million.
In 2024 the company repurchased about 3.9 million shares for $128 million; $373 million remained on the share repurchase authorization at year end.
Universal Health Services reported fourth-quarter 2024 net income attributable to UHS of $332.4 million, or $4.96 per diluted share, up from $216.4 million, or $3.16, a year earlier, on net revenues up 11.1% to $4.114 billion. For full-year 2024, net income was $1.142 billion, or $16.82 per diluted share, on net revenues of $15.828 billion. The company forecast 2025 net revenues of $17.020 billion to $17.364 billion and EPS-diluted of $18.45 to $19.95 per share.
Q4 2024 net income attributable to UHS: $332.4 million, or $4.96 per diluted share, versus $216.4 million, or $3.16, in Q4 2023
Q4 2024 net revenues rose 11.1% to $4.114 billion; full-year 2024 net revenues were $15.828 billion
2025 forecast: net revenues $17.020 billion to $17.364 billion; EPS-diluted $18.45 to $19.95 per share
Share repurchases in 2024 totaled approximately $598.5 million; about $824.4 million of authorization remained as of December 31, 2024
Koppers reported a fourth-quarter 2024 net loss of $10.2 million, or $0.50 per diluted share, versus net income of $12.9 million, or $0.59, a year earlier, as sales fell 7.1% to $477.0 million. The company also forecast 2025 sales of about $2.17 billion and adjusted EBITDA of about $280 million, both above 2024 levels, which may matter to shareholders if the outlook holds.
Q4 2024 net loss of $10.2 million ($0.50 per diluted share) vs. net income of $12.9 million ($0.59) in Q4 2023
Q4 2024 sales of $477.0 million, down 7.1%; adjusted EPS of $0.77 vs. $0.67 a year earlier
Full-year 2024 sales of $2.09 billion vs. $2.15 billion; diluted EPS of $2.46 vs. $4.14
2025 outlook: sales of about $2.17 billion, adjusted EBITDA of about $280 million, adjusted EPS of $4.75
Medical Properties Trust reported a fourth-quarter 2024 net loss of $413 million ($0.69 per share) and a full-year net loss of $2.4 billion ($4.02 per share), including about $415 million of impairments and fair market value adjustments tied to Prospect Medical Group and PHP Holdings. Normalized FFO fell to $0.18 per share for the quarter from $0.36 a year earlier and to $0.80 for the year from $1.59. The company said a $2.5 billion senior secured notes offering addresses all debt maturities through 2026.
Q4 2024 net loss of $413 million ($0.69 per share) versus $664 million ($1.11 per share) in Q4 2023
Q4 2024 normalized FFO of $0.18 per share versus $0.36; full-year 2024 normalized FFO of $0.80 versus $1.59
Full-year 2024 net loss of $2.4 billion ($4.02 per share) versus $556 million ($0.93 per share) in 2023
Private offering of more than $2.5 billion of senior secured notes due 2032 at a blended coupon of 7.885%
Xencor reported fourth-quarter and full-year 2024 results. Full-year revenue fell to $110.5 million from $174.6 million, and the net loss attributable to Xencor widened to $232.6 million, or $(3.58) per share, from $133.1 million, or $(2.20) per share. For shareholders, the filing also gives a 2025 year-end cash guidance range of $535 million to $585 million.
Q4 2024 revenue was $52.8 million, up from $51.0 million, driven mainly by Amgen and Novartis milestone revenue
Q4 2024 net loss attributable to Xencor was $45.6 million, or $(0.62) per share, versus $26.1 million, or $(0.43), a year earlier
Cash, cash equivalents and marketable debt securities were $706.7 million at December 31, 2024, up from $697.0 million
Company expects to end 2025 with between $535 million and $585 million in cash and marketable debt securities
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.